- Clarification 17 December 2020
Exosome-based candidates move into the clinic
Access options
Subscribe to Journal
Get full journal access for 1 year
$259.00
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.
Nature Reviews Drug Discovery 20, 6-7 (2021)
Updates & Corrections
-
Clarification 17 December 2020: The description of the first agent from Codiak to enter clinical trials has been updated to ‘engineered exosome-based therapeutic’ to distinguish it from non-engineered exosome-based therapeutics, which are not the focus of the article.